Evidence map›Paper›PMID 38668728›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2024

Generation of an Inhibitory NK Cell Subset by TGF-β1/IL-15 Polarization.

Douglas C Chung, Carlos R Garcia-Batres, Douglas G Millar, Stephanie W Y Wong, Alisha R Elford, Jessica A Mathews, Ben X Wang, Linh T Nguyen, Patricia A Shaw, Blaise A Clarke and 4 more

Abstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Natural Killer Cells: Dual Regulators and Therapeutic Targets in Multiple Sclerosis Immunopathogenesis.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Origin of Hypofunctional CD103European journal of immunology · 2025
    Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Douglas C ChungDepartment of Immunology, University of Toronto, Toronto, ON, Canada.ORCID 0000-0001-7971-3051
Carlos R Garcia-BatresTumour Immunotherapy Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0009-0005-2447-0685
Douglas G MillarTumour Immunotherapy Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-8640-7148
Stephanie W Y WongDepartment of Immunology, University of Toronto, Toronto, ON, Canada.
Alisha R ElfordTumour Immunotherapy Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Jessica A MathewsToronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.ORCID 0000-0003-2926-8222
Ben X WangTumour Immunotherapy Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Linh T NguyenTumour Immunotherapy Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0003-3470-1318
Patricia A ShawDivision of Gynecologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Blaise A ClarkeDivision of Gynecologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Marcus Q BernardiniDivision of Gynecologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0001-7022-8308
Adrian G SacherDepartment of Immunology, University of Toronto, Toronto, ON, Canada.
Sarah Q CromeDepartment of Immunology, University of Toronto, Toronto, ON, Canada.ORCID 0000-0001-5117-7453
Pamela S OhashiDepartment of Immunology, University of Toronto, Toronto, ON, Canada.ORCID 0000-0003-2915-9317

Funding

Canadian Government | Canadian Institutes of Health Research (CIHR) 143220Canadian Government | Canadian Institutes of Health Research (CIHR) 184713CCS | Canadian Cancer Society Research Institute (CCSRI) 706152Wolfond Immunotherapy Fund n/a
6 · The paper itself

Abstract

NK cells have been shown to exhibit inflammatory and immunoregulatory functions in a variety of healthy and diseased settings. In the context of chronic viral infection and cancer, distinct NK cell populations that inhibit adaptive immune responses have been observed. To understand how these cells arise and further characterize their immunosuppressive role, we examined in vitro conditions that could polarize human NK cells into an inhibitory subset. TGF-β1 has been shown to induce regulatory T cells in vitro and in vivo; we therefore investigated if TGF-β1 could also induce immunosuppressive NK-like cells. First, we found that TGF-β1/IL-15, but not IL-15 alone, induced CD103+CD49a+ NK-like cells from peripheral blood NK cells, which expressed markers previously associated with inhibitory CD56+ innate lymphoid cells, including high expression of GITR and CD101. Moreover, supernatant from ascites collected from patients with ovarian carcinoma also induced CD103+CD49a+ NK-like cells in vitro in a TGF-β-dependent manner. Interestingly, TGF-β1/IL-15-induced CD103+CD56+ NK-like cells suppressed autologous CD4+ T cells in vitro by reducing absolute number, proliferation, and expression of activation marker CD25. Collectively, these findings provide new insight into how NK cells may acquire an inhibitory phenotype in TGF-β1-rich environments.

Indexed as

Interleukin-15Killer Cells, NaturalTransforming Growth Factor beta1Antigens, CDCD56 AntigenCells, CulturedFemaleHumansIntegrin alpha ChainsLymphocyte ActivationLymphocyte SubsetsOvarian Neoplasmsalpha E integrinsAntigens, CDCD56 AntigenIL15 protein, humanIntegrin alpha ChainsInterleukin-15Transforming Growth Factor beta1

Identifiers

PMID38668728
PMCPMC11149900

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.